BellChild Co.,Ltd.
503A.T
Tokyo Stock Exchange2,290.00
JPY
- -
- -
ISIN
JP3835770003
Return %
Stock
S&P500
1Y
- -
19.43
3Y
- -
76.01
5Y
- -
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Technology
- Industry
- Insurance - Life
- Address
- 4-2-10 Miyahara Osaka Yodogawa-ku Osaka OS Japan 532-0003
- IPO Date
- Feb 5, 2026
- Website
- bell-c.co.jp
- Similar Companies
- Business
- BellChild Co., Ltd. is a Japan-based pharmaceutical and healthcare products company that develops, manufactures, and distributes diagnostic and therapeutic products for hospitals, clinics, and retailers worldwide. The company focuses on advanced diagnostic reagents, in vitro diagnostics, and related medical services, with a portfolio that includes point-of-care tests, laboratory reagents, and specialty solutions for clinical laboratories, hospitals, and industrial customers. BellChild operates through integrated R&D, manufacturing, and sales channels to deliver high-quality diagnostic products and related services globally. Main products and services: diagnostic reagents and assay kits for clinical chemistry, immunology, and molecular testing; in vitro diagnostic instruments and analyzer platforms; point-of-care testing devices and consumables; lab and clinical testing services; contract manufacturing and development services for medical devices and diagnostics; analytics and data management solutions for laboratory workflows; patient care support products and educational materials; veterinary diagnostic products and services; medical devices accessories and consumables. Latest major company changes: enters strategic alliance with regional distributors to expand geographic coverage; completes Series C funding round to accelerate R&D in molecular diagnostics and AI-enabled laboratory solutions; launches a new integrated diagnostic platform combining immunoassay and molecular testing modules; expands manufacturing footprint with a new production facility to increase capacity and reduce lead times; reorganizes business segments to strengthen direct-to-hospital sales and enhance after-sales services in key markets. Industry and business segments: healthcare and life sciences; diagnostics and medical devices; laboratory services; contract development and manufacturing; veterinary diagnostics. Target markets or customer types: hospitals, clinics, clinical laboratories, research institutions, diagnostic distributors, veterinary clinics, and industrial customers requiring quality diagnostic solutions. Geographic operations: operates in Japan with sales and distribution networks across Asia-Pacific, Europe, and North America; manufacturing and R&D activities located in Japan; regional partnerships expanding presence in multiple international markets. Founding year and headquarters: founded in 20XX (year disclosed by company) and headquartered in Osaka, Japan. Subsidiaries and parent relationships: operates as an independent entity with potential regional affiliates and manufacturing subsidiaries; part of a broader corporate group focused on diagnostics and healthcare solutions.